Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ORAL-LYO-FMT
- Development stage
- Phase 2
- Lead developer
- Seres Therapeutics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
ORAL-LYO-FMT is an oral, lyophilized (freeze-dried) formulation of fecal microbiota transplant (FMT) developed by PharmaPlanter Technologies. It is a live biotherapeutic product designed to restore a healthy gut microbiome. The drug is currently being evaluated in a Phase 2 adaptive basket trial for its efficacy in treating diarrhea-predominant irritable bowel syndrome (IBS-D) and preventing recurrent Clostridioides difficile infection (rCDI). [2] By introducing a diverse community of microorganisms via oral capsules, the therapy aims to modulate the recipient's gut flora, which is thought to alleviate the symptoms of IBS-D and prevent the recurrence of pathogenic infections like C. difficile. [5, 7, 8]
- Other names
- fecal microbiota transplantoral lyophilized fecal microbiota therapy
Beyond the preview
Go deeper on ORAL-LYO-FMT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ORAL-LYO-FMT.